CRCHD Dialogue on Disparities
Find the latest updates, spotlights, and news from CRCHD.
-
EIAP Announces Successes from First Two CohortsThe Early Investigator Advancement Program announces Cohort I and II Scholars who have attained an R01 or equivalent award.
-
President Biden Appoints EIAP Scholar Dr. Edjah Nduom to Serve on the National Cancer Advisory BoardThe NCI Center to Reduce Cancer Health Disparities is pleased to share exciting news about an Early Investigator Advancement Program (EIAP) scholar—Dr. Edjah Nduom—who was appointed by President Biden to the National Cancer Advisory Board (NCAB) on May 10, 2024.
-
CRCHD Announces the Establishment of Cancer Equity Leaders to Contribute to Health Equity Efforts, Host 2025 EventThe NCI Center to Reduce Cancer Health Disparities is thrilled to announce the Cancer Equity Leaders (CEL), a diverse team of premier cancer research leaders who will reimagine and transform the future of cancer health equity.
-
Dr. Jill Bargonetti on Addressing Systemic Barriers to Including African American Women in Breast Cancer ResearchThe CRCHD-supported Hunter College (HC)–Temple University–Fox Chase Cancer Center Partnership has made it possible for a newly supported pilot project to begin a study titled “Evaluating Black and African American Breast Cancer Populations for Therapeutic Targeting of Aberrant p53, MDM2, MDMX, and PARP signaling.” In this guest blog post, co-Investigator Jill Bargonetti, Ph.D., discusses what the partners bring to the study, what the team hopes to learn, and how the study incorporates community outreach.
-
Early Investigator Advancement Program Announces Third Cohort of Scholars
The cancer research enterprise needs a continuous flow of talent through the research career pipeline to thrive. One critical juncture is the transition from junior investigator to established investigator. To this end, NCI launched the Early Investigator Advancement Program (EIAP) with the support of the NCI Equity Council in 2021. EIAP is a trans-NCI program that aims to assist cancer researchers and clinician scientists in attaining an R01 or R-type equivalent funding. We are pleased to announce and welcome the third cohort of EIAP scholars.